Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (EVACEL)

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Determine wether 24 months treatment with everolimus prolongs progression free survival rate (based on a central assessment) after embolisation ou chemoembolisation for liver metastases.

• H0 a 24 months progression free survival rate less than 35% is unacceptable
• H1 a 24 months progression free survival rate greater than 35% would show that everolimus treatment is beneficial, the expected 24 months progression free survival rate being 50%

Study Overview

• Status: Completed
• Conditions: Neuroendocrine Tumors; Hepatic Metastases; Metastases
• Intervention / Treatment: Drug: Everolimus; Device: embolization; Drug: Doxorubicin

• Study Type: Interventional
• Enrollment (Actual): 74
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Angers, France
    • CHU - Hôtel Dieu
  • Bobigny, France
    • Hôpital Avicenne
  • Bordeaux, France
    • Hôpital Saint André
  • Caen, France
    • Hôpital Côte de Nacre
  • Clermont Ferrand, France
    • CHU - Estaing
  • Clichy, France
    • Hôpital Beaujon
  • Dijon, France
    • CHU - Hôpital François Mitterand
  • Dijon, France
    • Centre GF Leclerc
  • Lyon, France
    • Hôpital Edouard Herriot
  • Marseille, France
    • CHU La Timone
  • Orléans, France
    • CHR
  • Paris, France
    • Hôpital Européen Georges Pompidou
  • Paris, France
    • CHU Cochin
  • Reims, France
    • Hopital Robert Debre
  • Rouen, France
    • CHU
  • Toulouse, France
    • Hôpital Rangueil
  • Tours, France
    • Hôpital Trousseau
  • Villejuif, France
    • Institut Gustave Roussy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Well differentiated (grade 1 and 2 according to WHO classification 2010 appendix 2), histologically-proven endocrine tumor of the gastrointestinal tract (TENpath review mandatory),
• Measurable liver metastasis (or metastases) as defined in RECIST v1.1 that are unresectable and inaccessible to radiofrequency ablation-type local treatment
• Hepatic arterial embolization or chemoembolization indicated for tumor size reduction, confirmed in an multidisciplinary team (MDT) meeting, due to the progressive nature of the liver metastases (morphological progression during the past 12 months as defined in RECIST v1.1)
• Age ≥ 18 years
• WHO performance status ≤ 2
• No contraindications to embolization or chemoembolization or everolimus
• Satisfactory laboratory assessments:Neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, Hb > 10 g/dL, serum bilirubin ≤ 1.5 x the upper limit of normal (ULN), INR < 1.3 (or < 3 for patients on anticoagulant therapy) ALT and AST ≤ 5 x ULN, creatinine ≤ 1.5 x ULN, fasting serum cholesterol ≤ 300 mg/dL or 7.75 mmol/L and triglycerides ≤ 2.5 x ULN (if either or both of these limits are exceeded, the patient may only be included into the study after institution of appropriate lipid-lowering therapy)
• Complete resolution of toxic effects of any prior treatments, or persistence at grade 1 at most (CTCAE version 4.0)
• Minimum time since previous treatment: 28 days
• Patient has been informed and has signed an informed consent form, after verification of the eligibility criteria
• Patient covered by a French national health insurance scheme

Exclusion Criteria:

• Duodenopancreatic neuroendocrine tumor
• Poorly differentiated and/or grade 3 endocrine tumor,
• Embolization or chemoembolization indicated for symptomatic control only
• Prior hepatic TACE or embolization
• Prior treatment with an mTOR inhibitor (somatostatin analogs to control secretion are permitted)
• Symptomatic bone metastasis (or metastases)
• Any uncontrolled progressive disease: hepatic failure, renal failure, respiratory failure, NYHA class III-IV congestive heart failure, unstable angina, myocardial infarction, significant arrhythmia
• Interstitial lung disease
• Uncontrolled diabetes, defined by HbA1c > 8%
• Chronic corticosteroid or immunosuppressant therapy
• Hypersensitivity to everolimus, other rapamycin derivatives, or one of the excipients
• Major surgery, open biopsy, or significant traumatic lesion during the 28 days prior to starting the investigational treatment Incompletely healed wound or foreseeable need for major surgery during the study
• Contraindication to vascular occlusion procedures: Portal thrombosis, biliodigestive anastomosis
• Malignancy during the past 5 years, with the exception of curatively treated basal cell skin carcinoma or in situ cervical cancer
• Foreseeable non-compliance
• Medical, geographic, sociological, psychological, or legal situation that would preclude the patient from completing the study or signing an informed consent form
• Pregnant or breast-feeding women
• Men or women of child-bearing potential not using effective contraception
• Concurrent participation in another investigational study that could affect the primary endpoint of this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: embolization or chemoembolization plus everolimus; After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).	Drug: Everolimus; 10 mg per day of everolimus during 24 months or until progression disease; Device: embolization; 2 sessions embolization with spheric particles; Other Names: spheric particules of 100 to 500 µm; Drug: Doxorubicin; 2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine; Other Names: Chemoembolization

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Hepatic Progression Free Survival at 24 Months	Hepatic progression free survival rate as defined in RECIST 1.1 (with death considered as progression) during the 24 months of treatment with everolimus. Progression-free survival rate (PFS) (based on the investigator) according to RECIST v1.1 according to RECIST v1.1 will be defined as the time from the date of inclusion to the date of hepatic progression or death (due to any cause). For patients who are alive with no hepatic progression, it will be defines as the time from the date of inclusion and the date of the last tumor assessment.	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (Hepatic or Not)	Progression-free survival rate was defined as the time from the date of inclusion to the date of disease progression (hepatic or not) evaluated by RECIST V1.1 criteria or death (due to any cause) or the date of the last news for alive patients	From randomization until the date of first progression (clinical or radiological) or death from any cause whichever came first, assessed up to 3 years
Overall Survival	Overall survival was defined as the time from the date of inclusion to the date of death, regardless of the cause of death, or the date of last contact for patients who are alive.	From randomization until death or last news for alive patients

Collaborators and Investigators

• Sponsor: Federation Francophone de Cancerologie Digestive
• Investigators: Principal Investigator: Thomas WALTER, PhD, Hopital Edouard Herriot - Lyon

Publications and helpful links

General Publications

• Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baere T; FFCD 1104 investigators/investigators. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. Eur J Cancer. 2019 Dec;123:92-100. doi: 10.1016/j.ejca.2019.09.021. Epub 2019 Oct 31.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2012
• Primary Completion (Actual): September 1, 2018
• Study Completion (Actual): April 1, 2019

Study Registration Dates

• First Submitted: August 22, 2012
• First Submitted That Met QC Criteria: August 30, 2012
• First Posted (Estimated): September 5, 2012

Study Record Updates

• Last Update Posted (Actual): September 25, 2024
• Last Update Submitted That Met QC Criteria: September 2, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: metastases; cancer; liver; hepatic; neuroendocrine tumors; gastrointestinal tract
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neoplastic Processes; Neoplasm Metastasis; Neuroendocrine Tumors; Endocrine Gland Neoplasms; Neoplasms, Second Primary; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Protein Kinase Inhibitors; Antibiotics, Antineoplastic; MTOR Inhibitors; Doxorubicin; Everolimus
• Other Study ID Numbers: FFCD 1104